Stoke Therapeutics (NASDAQ:STOK) versus Sana Biotechnology (NASDAQ:SANA) Head-To-Head Comparison

Stoke Therapeutics (NASDAQ:STOK) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Volatility and Risk

Stoke Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500.

Earnings & Valuation

This table compares Stoke Therapeutics and Sana Biotechnology”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42 million	10.23	-$6.89 million	($2.81)	-10.78
Sana Biotechnology	N/A	N/A	-$244.17 million	($0.93)	-3.34

Stoke Therapeutics has higher revenue and earnings than Sana Biotechnology. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stoke Therapeutics and Sana Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-48.84%	-42.27%
Sana Biotechnology	N/A	-108.01%	-40.68%

Analyst Recommendations

This is a summary of recent recommendations for Stoke Therapeutics and Sana Biotechnology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1	1	9	0	2.73
Sana Biotechnology	1	1	7	0	2.67

Stoke Therapeutics currently has a consensus price target of $41.83, indicating a potential upside of 38.06%. Sana Biotechnology has a consensus price target of $9.50, indicating a potential upside of 205.47%. Given Sana Biotechnology’s higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Stoke Therapeutics.

Insider and Institutional Ownership

88.2% of Sana Biotechnology shares are owned by institutional investors. 9.5% of Stoke Therapeutics shares are owned by insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Sana Biotechnology beats Stoke Therapeutics on 8 of the 13 factors compared between the two stocks.

About Stoke Therapeutics

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

About Sana Biotechnology

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company’s product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin’s lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.